Postoperative and Opioid Free Anesthesia

Only registered users can translate articles

The link is saved to the clipboard

StatusTerminated

Keywords

Abstract

Since the 1960's, intraoperative administration of opioids is considered a keystone of anesthesia as well as hypnotics and muscle relaxants. Synthetic opioids were introduced to achieve hemodynamic stability during anesthesia. They allow an inhibition of the sympathetic system without cardiovascular collapse and histamine release. Since then, anesthesia has changed from inhalation to multimodal anesthesia with lower doses of hypnotic. In 2017, the intraoperative objectives of hypnosis, hemodynamic stability, immobility and anticipation of postoperative analgesia can be achieved without opioids. Moreover, opioid administration consequences are neither scarce nor benign for the patient. Perioperative opioids are associated with nausea and vomiting, sedation, ileus, confusion/delirium, respiratory depression, increased postoperative pain and morphine consumption, immunodepression, hyperalgesia and chronic postoperative pain. Among these complications, hypoxemia, ileus and confusion/delirium are the most frequent.

Efficacious multimodal analgesia and anesthesia are the basis of successful fast-track surgery. These multidrug regimens aim at decreasing postoperative pain, intra- and postoperative opioid requirements, and subsequently, opioid-related adverse effects and to fasten recovery. Opioid-free postoperative analgesia has been recommended for more than 10 years. Opioid-free anesthesia (OFA) is based on the idea that hemodynamic stability can be achieved without opioids during anesthesia. OFA is multimodal anesthesia associating hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics, anti-inflammatory drugs and alpha-2 agonists (Dexmedetomidine).

Proofs of the effect of OFA on reducing opioid-related adverse effects after major or intermediate non-cardiac surgery are still scarce. We hypothesized that the reduced opioid consumption during and after surgery allowed by OFA compared with standard of care will be associated with a reduction of postoperative opioid-related adverse events.

Dates

Last Verified:	09/30/2019
First Submitted:	10/12/2017
Estimated Enrollment Submitted:	10/18/2017
First Posted:	10/19/2017
Last Update Submitted:	10/15/2019
Last Update Posted:	10/17/2019
Actual Study Start Date:	11/28/2017
Estimated Primary Completion Date:	01/28/2019
Estimated Study Completion Date:	06/18/2019

Condition or disease

Anesthesia

Opioid-Related Disorders

Intervention/treatment

Drug: Dexmedetomidine

Drug: Control

Phase

Phase 3

Arm Groups

Arm	Intervention/treatment
Experimental: Dexmedetomidine	Drug: Dexmedetomidine Opioid-free anesthesia
Active Comparator: Control	Drug: Control Opioid anesthesia

Eligibility Criteria

Ages Eligible for Study	18 Years To 18 Years
Sexes Eligible for Study	All
Accepts Healthy Volunteers	Yes
Criteria	Inclusion Criteria: - Undergoing a scheduled major or intermediate non-cardiac surgery, - Benefiting from the health insurance system, - Having signed an informed consent. Exclusion Criteria: - Pregnant or breast feeding women, - Allergy to dexmedetomidine or one of its excipients, - Allergy to one of the drugs used for anesthesia or one of their excipients, - Urgent surgery, - Intracranial surgery, - Transplant surgery or transplanted patients, - Surgery with planned regional anesthesia, - Outpatient surgery, - Atrioventricular block, intraventricular or sinoatrial block, - Treatment by chronic betablockers and HR < 50 bpm, - Heart failure with LVEF < 40%, - Adam-Stokes syndrome, - Epilepsy or seizures, - Uncontrolled hypotension, - Acute cerebral pathology, - Obstructive sleep apnea syndrome, - Severe hepatic insufficiency (Prothrombin Ratio < 15%), - Patients in whom the CAM-ICU cannot be performed (deaf patients for example) - Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.

Outcome

Primary Outcome Measures

1. Occurence of a severe postoperative opioid-related adverse event defined as : postoperative hypoxemia or postoperative ileus (POI) or postoperative cognitive dysfunction (POCD). [Within the first 48 hours after extubation]

Postoperative hypoxemia is defined as an oxygen saturation (SpO2) < 95% with a need for oxygen supplementation within the first 48h after extubation; the duration of oxygen treatment will also be recorded. Postoperative ileus is defined as an absence of flatus or stools within the first 48h after extubation. Postoperative cognitive dysfunction will be evaluated using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) by a care provider (either anesthesiologist or nurse).

Secondary Outcome Measures

1. Number of episodes of postoperative pain (numeric rating scale ≥ 3), at rest [Within 48 hours after extubation]

2. Opioid consumption [During the 48 hours following extubation]

3. Time between the end of remifentanil or dexmedetomidine administration and an Aldrete score > 9 (when applicable) [Within 48 hours after extubation]

4. Time between the end of remifentanil or dexmedetomidine administration and extubation [Hour 0 = extubation]

5. Rate of unscheduled admission in intensive care unit [Within 48 hours after extubation]

6. Number of postoperative nausea and vomiting (PONV) episodes [During the 48 hours following extubation]

7. Hospital length of stay (max 28 days) defined as the number of days after extubation before first hospital discharge [Day 28]

8. Number of bradycardia, hypotension and hypertension events during surgery and number of rescue medications during surgery [During surgery (maximum duration of 7 hours)]

Bradycardia is defined as the number of episodes with atropine administration. Hypotension is defined as mean arterial blood pressure < 65 mmHg. Hypertension is defined as mean arterial blood pressure > 90 mmHg.

Postoperative and Opioid Free Anesthesia

Keywords

morphine

nausea

vomiting

hypoxia

inflammation

respiratory insufficiency

ileus

delirium

hyperalgesia

histamine

anti inflammatory